StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.80+0.10 (+0.60%)

Close on Nov 17, 2026Market cap $3.06BP/E –Yield –

Xeris Biopharma enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Xeris Biopharma's enterprise value was $3.00B on Nov 11, 2026, against $1.32B a year earlier. Over the last 5 years it ranged from $6.24M to $3.00B, with a median of $346.90M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$3.00B+110.1%
2025Dec 31, 2025$1.43B+216.6%
2024Dec 31, 2024$450.78M+74.4%
2023Dec 29, 2023$258.48M+195.8%
2022Dec 30, 2022$87.40M-14.2%
2021Dec 31, 2021$101.86M–

More Xeris Biopharma figures

See a number that looks wrong?